Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone Acetate
35%
Adverse Event
15%
Anaplastic Thyroid Carcinoma
11%
Androgen
27%
Androgen Receptor
25%
Biological Marker
74%
Breast Cancer
12%
Cancer Survival
11%
Castration Resistant Prostate Cancer
55%
Chelating Agent
11%
Chemoradiation Therapy
32%
Chemotherapy
56%
Clinical Trial
14%
Colon Carcinoma
11%
Colorectal Carcinoma
11%
Copolymer
11%
Death Receptor
11%
Disease Free Survival
11%
Diseases
15%
Enzalutamide
13%
Erlotinib
11%
Glioblastoma
11%
Immunotherapy
16%
Isoflavone
11%
Kidney Metastasis
15%
Malignant Neoplasm
74%
Metastasis
13%
Micelle
11%
Modafinil
11%
Neoplasm
99%
Osimertinib
11%
Overall Survival
62%
Patient History of Chemotherapy
11%
Pazopanib
37%
Pharmacokinetics
17%
Phospholipase A2
11%
Placebo
16%
Polymersome
11%
Prednisone
40%
Progression Free Survival
35%
Prostate Cancer
51%
Rectum Cancer
47%
Renal Cell Carcinoma
37%
Secretory Phospholipase A2
11%
Sunitinib
25%
Thyroid Cancer
11%
Thyroid Papillary Carcinoma
11%
Tigilanol Tiglate
11%
Uterine Cervix Cancer
11%
Yttrium 90
11%
Medicine and Dentistry
Anaplastic Thyroid Carcinoma
11%
Androgen Receptor
23%
Ataxia Telangiectasia
11%
Biological Marker
58%
Breast Cancer
17%
Cancer
14%
Cancer Cell
14%
Cancer Surgery
25%
Cancer Survival
11%
Cancer-Related Fatigue
11%
Cell Free Nucleic Acid
11%
Circulating Tumor Cell
100%
Clear Cell Renal Cell Carcinoma
23%
Clinician
17%
Colorectal Carcinoma
57%
Death Receptor
11%
Disease
15%
Disease Free Survival
29%
DNA Extraction
11%
Epidermolysis Bullosa Dystrophica
13%
Exosome
11%
Gene Frequency
11%
Glioblastoma
11%
Immune Checkpoint Inhibitor
11%
Immunotherapy
26%
Liquid Biopsy
31%
Lung Cancer
11%
Lymphocyte Subpopulation
11%
Malignant Neoplasm
37%
Melanoma Cell
23%
Melanoma Cell Line
11%
Mesenchymal-Epithelial Transition
14%
Metastatic Carcinoma
20%
Metastatic Colorectal Cancer
12%
Neoplasm
62%
Nucleic Acid
15%
Nutrition Assessment
11%
Osimertinib
11%
Overall Survival
17%
Personalized Medicine
13%
Polo Like Kinase 1
23%
Proliferating Cell Nuclear Antigen
11%
Prospective Cohort Study
11%
Prostate Cancer
12%
Radiation Therapy
23%
Rectum Cancer
35%
Sarcomatoid
11%
Selective Internal Radiation Therapy
11%
Tyrosine-Kinase Inhibitor
11%
Yttrium 90
11%
Immunology and Microbiology
Ataxia Telangiectasia
11%
Biological Activity
11%
Blood Sampling
11%
Body Fluid
11%
Cancer Cell
14%
Cancer Stem Cell
23%
Cancer Survival
18%
Carcinoma Cell
11%
Cell Isolation
9%
Circulating Tumor Cell
56%
Colon
11%
Conatumumab
11%
Cryopreservation
11%
Disease Free Survival
38%
DNA Binding Protein
5%
DNA Repair
8%
Drug Resistance
7%
Epithelial Mesenchymal Transition
47%
Ethylenediaminetetraacetic Acid
7%
Exosome
11%
Gamma Urogastrone
11%
Gene Expression Regulation
5%
Immunity
11%
Immunotherapy
23%
In Situ Hybridization
5%
Keratinocyte
5%
Lycopene
11%
Melanoma Cell
11%
Neural Cell Adhesion Molecule
11%
Overall Survival
26%
Pazopanib
11%
Prednisone
9%
Programmed Cell Death 1
11%
Programmed Death-Ligand 1
23%
Progression Free Survival
12%
Prostate
32%
Prostate Cancer Cell Line
11%
Prostate Specific Antigen
11%
Protein Stability
5%
Radioresistance
5%
Real-Time Polymerase Chain Reaction
5%
RNA Splicing
11%
Sensitive Detection
11%
Signal Transduction
11%
Squamous Cell
11%
Thyroid
11%
Toll-Like Receptor
5%
Transcriptome
5%
Tumor Cell
11%
Tumor Spheroid
11%